Richter Transformation to Hodgkin Lymphoma on Bruton's Tyrosine Kinase Inhibitor Therapy

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2018 Jul 7

PMID 29978754

Citations 3

Authors

Alankrita Taneja

Jade Jones

Stefania Pittaluga

Irina Maric

Mohammed Farooqui

Inhye E Ahn

Adrian Wiestner

Clare Sun

Affiliations

Soon will be listed here.

Citing Articles

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.

Woyach J, Ghia P, Byrd J, Ahn I, Moreno C, OBrien S Clin Cancer Res. 2023; 29(16):3065-3073.

PMID: 37314786 PMC: 10425728. DOI: 10.1158/1078-0432.CCR-22-3887.

Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.

Koshiishi M, Odate T, Nakagawa Y, Suzuki J, Kumagai T, Kawashima I Intern Med. 2021; 60(20):3305-3308.

PMID: 33896865 PMC: 8580765. DOI: 10.2169/internalmedicine.6979-20.

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.

Sun C, Nierman P, Kendall E, Cheung J, Gulrajani M, Herman S Blood. 2020; 136(1):93-105.

PMID: 32202637 PMC: 7332900. DOI: 10.1182/blood.2019003715.

References

Anderson M, Tam C, Lew T, Juneja S, Juneja M, Westerman D . Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017; 129(25):3362-3370. DOI: 10.1182/blood-2017-01-763003. View

Glavey S, Quinn J, McCloy M, Sargent J, McCartney Y, Catherwood M . Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. Eur J Haematol. 2017; 99(4):378-380. DOI: 10.1111/ejh.12911. View

Bockorny B, Codreanu I, Dasanu C . Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2011; 156(1):50-66. DOI: 10.1111/j.1365-2141.2011.08907.x. View

Giri S, Hahn A, Yaghmour G, Martin M . Ibrutinib has some activity in Richter's syndrome. Blood Cancer J. 2015; 5:e277. PMC: 5404220. DOI: 10.1038/bcj.2014.98. View

Innocenti I, Rossi D, Trape G, Autore F, Larocca L, Gomes V . Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018; . DOI: 10.1002/hon.2502. View

Mato A, Nabhan C, Thompson M, Lamanna N, Brander D, Hill B . Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103(5):874-879. PMC: 5927982. DOI: 10.3324/haematol.2017.182907. View

Tsang M, Shanafelt T, Call T, Ding W, Chanan-Khan A, Leis J . The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015; 125(10):1676-8. PMC: 4351511. DOI: 10.1182/blood-2014-12-610782. View

Davids M, Roberts A, Seymour J, Pagel J, Kahl B, Wierda W . Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017; 35(8):826-833. PMC: 5455685. DOI: 10.1200/JCO.2016.70.4320. View

Sachanas S, Pangalis G, Moschogiannis M, Yiakoumis X, Koulieris E, Tsirkinidis P . Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?. Anticancer Res. 2017; 37(6):3277-3280. DOI: 10.21873/anticanres.11692. View

10.

Momose H, Jaffe E, Shin S, Chen Y, Weiss L . Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus. Am J Surg Pathol. 1992; 16(9):859-67. DOI: 10.1097/00000478-199209000-00004. View

11.

Hamadani M, Balasubramanian S, Hari P . Ibrutinib in Refractory Classic Hodgkin's Lymphoma. N Engl J Med. 2015; 373(14):1381-2. DOI: 10.1056/NEJMc1505857. View

12.

Master S, Leary C, Takalkar A, Coltelingam J, Mansour R, Mills G . Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant. Case Rep Oncol. 2017; 10(2):534-541. PMC: 5498945. DOI: 10.1159/000477338. View

13.

Smith C . Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Semin Cancer Biol. 2016; 45:36-49. DOI: 10.1016/j.semcancer.2016.11.008. View

14.

Ahn I, Underbayev C, Albitar A, Herman S, Tian X, Maric I . Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017; 129(11):1469-1479. PMC: 5356450. DOI: 10.1182/blood-2016-06-719294. View